Product Description
Saxagliptin is used along with diet and exercise to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors.
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | General Diabetes | Type 2 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Type 1 Diabetes
Known Adverse Events: Headache | Respiratory Tract Infections | Edema | Nasopharyngitis | Pharyngitis | Diarrhea | Dyslipidemia
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Brazil, Canada, Chile, Colombia, Finland, India, Israel, Italy, Korea, Malaysia, Mexico, New Zealand, Philippines, Poland, Russia, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Paediatric study Dapagliflozin/Saxagliptin in type 2 diabetes mellitus | P3 |
Completed |
Type 2 Diabetes |
2023-09-08 |
|
| D1680C00019 | P3 |
Completed |
Type 2 Diabetes |
2023-02-01 |